Business Context and Reporting Period
Company: PMGC Holdings Inc. (formerly Elevai Labs Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: April 9, 2025
Reporting Period: Event-based (Effective Date of Agreement: April 9, 2025)
PMGC Holdings Inc., through its wholly owned subsidiary Northstrive Biosciences Inc., entered into a Development and License Agreement with YuvaBio Biosciences, Inc. The agreement focuses on the development of mitochondrial science-related technology using artificial intelligence (AI) for the treatment of Cardiac Diseases and Obesity.
Key Financial Metrics
This filing is a Current Report (Form 8-K) detailing a corporate event and does not contain audited financial statements, revenue, profit, cash flow, or balance sheet data.
- Revenue/Profit/Cash Flow: Not provided in this filing.
- Debt/Liquidity: Not provided in this filing.
- Transaction Economics: The agreement includes an upfront fee, phase-based payments, developmental milestone payments, and royalties on Net Sales. Specific monetary values for these payments are redacted or not disclosed in the summary text.
Material Changes
The primary material change is the execution of a strategic partnership to leverage AI for drug discovery.
- New Partnership: Collaboration with YuvaBio to develop AI-driven mitochondrial technology.
- Scope: Exclusive worldwide license for Northstrive within the "Field of Use" defined as Cardiac Diseases and Obesity.
- Intellectual Property: Northstrive will own "Northstrive Product IP" related to the development and commercialization of products derived from the program, while YuvaBio retains ownership of its AI methods and software code ("YuvaBio Sole Foreground IP").
Guidance, Outlook, and Risks
Outlook and Program Structure: The parties will collaborate on a multi-phase AI Development Program. YuvaBio will identify drug candidates to improve mitochondrial health and cardiometabolic function, testing computational findings on custom assays.
Termination and Contingencies:
- Term: The agreement expires on a product-by-product basis upon the expiration of the Royalty Term (latest of patent expiration or 12 years from first commercial sale).
- Termination for Cause: Either party may terminate for bankruptcy, cessation of business, or material breach.
- Termination for Convenience: Northstrive may terminate with 10 days' written notice. If terminated prior to program completion, Northstrive must pay an early termination fee and cover YuvaBio's incurred or non-cancellable costs.
Risks:
- Success depends on the efficacy of the AI Development Program and the identification of viable drug candidates.
- Financial obligations include upfront fees and potential termination costs.
Investor Verification Checklist
- Verify the specific amounts of the upfront fee, milestone payments, and royalty rates in the full text of Exhibit 10.1 (Development and License Agreement), as these are redacted in the summary.
- Confirm the detailed definition of the "Royalty Term" and the specific patent rights covered in the full agreement.
- Review the press release (Exhibit 99.1) for additional management commentary on the strategic rationale.
- Assess the financial impact of potential early termination fees on the company's liquidity.